NextCure Announces Workforce Reductions
NextCure has disclosed recent layoffs as the company prepares for upcoming strategic developments.
Filings · News reference
NextCure reported its third quarter 2026 financial results and provided an update on its pending merger with Avere Therapeutics, including the effectiveness of its S-4 registration statement.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
NextCure has disclosed recent layoffs as the company prepares for upcoming strategic developments.
NextCure, Inc. announced the termination of Chief Medical Officer Udayan Guha, effective October 31, 2026, in connection with the company's pending merger with Avere Therapeutics.
Filed: 2026-10-30 AccNo: 0001104659-26-120405 Size: 161 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's after-market session. The company's market cap stands at $1.9 billion. As per the news, the Q2 earnings report came out